title: Committee opinion no. 588: human papillomavirus vaccination.
abstract: The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescent immunization platform to help reduce the incidence of anogenital cancers and genital warts associated with HPV infection. The quadrivalent HPV vaccine is approved for use in males and females, whereas the bivalent HPV vaccine is approved for use only in females. For those not vaccinated at the target age, catch-up vaccination is recommended up to age 26 years. The American College of Obstetricians and Gynecologists endorses these recommendations. Although obstetrician-gynecologists are not likely to care for many patients in the initial HPV vaccination target group, they have the opportunity to educate mothers about the importance of vaccinating their children at the recommended age and are critical to vaccinating adolescent girls and young women during the catch-up period. Obstetrician-gynecologists should advise patients and parents that HPV vaccines are most effective in preventing genital cancers when administered before the onset of sexual activity. However, sexually active individuals can receive some benefit from the vaccination because exposure to all HPV types prevented by the vaccines is unlikely in persons aged 13 years through 26 years. Although HPV vaccination in pregnancy is not recommended, neither is routine pregnancy testing before vaccination. Lactating women can receive either HPV vaccine. The need for ongoing cervical cytology screening should be emphasized in all women aged 21 years and older, even those who received HPV vaccination before the onset of sexual activity.
mesh_terms: D000293:Adolescent; D000328:Adult; D001005:Anus Neoplasms / Q000517:prevention & control / Q000821:virology; D002648:Child; D005260:Female; D005833:Genital Neoplasms, Female / Q000517:prevention & control / Q000821:virology; D005834:Genital Neoplasms, Male / Q000517:prevention & control / Q000821:virology; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D009062:Mouth Neoplasms / Q000517:prevention & control / Q000821:virology; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D010353:Patient Education as Topic; D061214:Patient Safety; D018579:Patient Selection; D014611:Vaccination / Q000379:methods / Q000592:standards; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines